Medical Condition News

RSS

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Matthew Feddersen and Blake Marggraff from Lafayette, Calif. were awarded the top prize at the Intel International Science and Engineering Fair, a program of Society for Science & the Public. They received $75,000 and the Gordon E. Moore Award, in honor of the Intel co-founder and retired chairman and CEO, for developing a potentially more effective and less expensive cancer treatment that places tin metal near a tumor before radiation therapy.

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Vitamin D may improve exercise capacity, respiratory muscle strength in COPD patients

Vitamin D supplements may help patients with chronic obstructive pulmonary disease (COPD) get more from their pulmonary rehabilitation programs, according to a study conducted by researchers from Belgium.

16 May 2011

Hospital patients with pneumonia may face risk of sudden cardiac arrest

Hospital patients with pneumonia may be at risk of experiencing sudden cardiac arrest, often with few or no warning signs, according to research from the University of Chicago Medical Center under the auspices of the American Heart Association's Get with the Guidelines project.

16 May 2011

Mylan introduces Cyclobenzaprine HCl ER Capsules, a muscle relaxant

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) Capsules, 15 mg and 30 mg. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Cyclobenzaprine HCl ER Capsules and was awarded 180 days of marketing exclusivity.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

Genetic link for depression found: Study

Researchers have for the first time confirmed a specific genetic link to depression, according to new evidence published in the American Journal of Psychiatry on Monday. This finding was made independently by research teams in the UK and US, is expected to lead to a better biological understanding of the condition and eventually to more effective antidepressants.

15 May 2011

Cockroaches are a leading trigger of allergies and asthma attacks

May marks National Allergy and Asthma Awareness Month, and the National Pest Management Association warns families that cockroaches are a leading trigger of allergies and asthma attacks. The pests' saliva, droppings and decomposing bodies contain allergen proteins known to trigger allergies and increase the severity of asthma symptoms, especially in children.

13 May 2011

The Leonardo da Vinci Prize competition invites project submissions

International philanthropists, prestigious Universities, Hospitals, Order of Physicians, Public Administrations support and sponsor this initiative to follow scientific procedures to identify solutions with the highest potential to reduce premature cancer death and cost.

13 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets.

13 May 2011

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Risperidone Orally Disintegrating Tablets, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the generic version of Ortho-McNeil's Risperdal M-Tab, a treatment for schizophrenia.

13 May 2011

PAF, Breakaway from Cancer partner for awareness campaign

The Patient Advocate Foundation – a national non-profit organization that provides professional case management services to tens of thousands of patients every year who are unable to obtain access to care because of financial or insurance denials - is pleased to partner with Breakaway from Cancer, a national fundraising and educational initiative founded by Amgen in 2005 as a complementary component to the company's sponsorship of the Amgen Tour of California, a world-class professional cycling competition, to raise awareness of the important resources available to cancer patients including prevention, education, patient care, advocacy, financial support and survivorship.

13 May 2011

Researcher says a comparison with epilepsy is an appropriate prism to view economics

Since 2008, the U.S. economy has been "seizing" uncontrollably. Now a Tel Aviv University researcher says that a comparison of the multifaceted economic downturn with the uncontrolled spasms of an epileptic is not inappropriate - and may say something about the origins of the disaster.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

PROTECT II study data in high-risk percutaneous coronary intervention to be presented at EuroPCR

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.

13 May 2011

Researchers untangle two distinct ways in which tumor-suppressor protein works

Researchers at the Stanford University School of Medicine have untangled two distinct ways in which a common, naturally occurring "tumor-suppressor" protein works.

13 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

Spouse caregivers may have high risk of cognitive impairment or dementia

An older individual who cares for a spouse with dementia may be at an increased risk of developing cognitive problems because of the lifestyle that was shared with the spouse and because of the stress of caring for a loved one who is ill.

13 May 2011

Medical Condition News

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

Vitamin D may improve exercise capacity, respiratory muscle strength in COPD patients

Hospital patients with pneumonia may face risk of sudden cardiac arrest

Mylan introduces Cyclobenzaprine HCl ER Capsules, a muscle relaxant

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

Genetic link for depression found: Study

Cockroaches are a leading trigger of allergies and asthma attacks

The Leonardo da Vinci Prize competition invites project submissions

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

China's SFDA approves TPI anti-diabetic drug Gliclazide

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

PAF, Breakaway from Cancer partner for awareness campaign

Researcher says a comparison with epilepsy is an appropriate prism to view economics

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

PROTECT II study data in high-risk percutaneous coronary intervention to be presented at EuroPCR

Researchers untangle two distinct ways in which tumor-suppressor protein works

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

Spouse caregivers may have high risk of cognitive impairment or dementia

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News